These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 24991796)

  • 21. Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors.
    Galderisi M; de Divitiis O
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):523-31. PubMed ID: 18520954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of angiotensin-converting enzyme inhibitory peptide LAP on vascular remodeling.
    Huang J; Luo M; Fang H; Zheng H; Shen Y; Li L; Deng Y; Xu H
    Clin Exp Hypertens; 2013; 35(6):437-43. PubMed ID: 23198680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.
    Ram CV
    Future Cardiol; 2009 Sep; 5(5):453-65. PubMed ID: 19715410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
    Ferrari R
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Marine fish-derived bioactive peptides as potential antihypertensive agents.
    Kim SK; Ngo DH; Vo TS
    Adv Food Nutr Res; 2012; 65():249-60. PubMed ID: 22361192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a review of the current evidence.
    Tsouli SG; Liberopoulos EN; Kiortsis DN; Mikhailidis DP; Elisaf MS
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):1-15. PubMed ID: 16703216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic investigations of novel indoxyl-based indolines: A drug target validation and Structure-Activity Relationship of angiotensin-converting enzyme inhibitors with cardiovascular regulation and thrombolytic potential.
    Manikandan A; Moharil P; Sathishkumar M; Muñoz-Garay C; Sivakumar A
    Eur J Med Chem; 2017 Dec; 141():417-426. PubMed ID: 29032034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of cardiovascular remodeling by the counter-regulatory axis of the renin-angiotensin system.
    Clarke C; Flores-Muñoz M; McKinney CA; Milligan G; Nicklin SA
    Future Cardiol; 2013 Jan; 9(1):23-38. PubMed ID: 23259473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prospective trends in the study of the therapeutic action of angiotensin-converting enzyme inhibitors in cardiovascular diseases].
    Novikova LS; Arabidze GG
    Ter Arkh; 1990; 62(1):118-23. PubMed ID: 2159193
    [No Abstract]   [Full Text] [Related]  

  • 30. [Drugs that block the angiotensin converting enzyme].
    Di Perr T
    Recenti Prog Med; 1985 May; 76(5):276-80. PubMed ID: 2992056
    [No Abstract]   [Full Text] [Related]  

  • 31. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
    Black HR
    Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular risk reduction in hypertension: angiotensin-converting enzyme inhibitors, angiotensin receptor blockers. Where are we up to?
    Sindone A; Erlich J; Lee C; Newman H; Suranyi M; Roger SD
    Intern Med J; 2016 Mar; 46(3):364-72. PubMed ID: 26968600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiotensin receptor blockers and cardiovascular protection: are we ONTARGET?
    Ram CV; Deedwania PC
    Am J Cardiol; 2008 Nov; 102(9):1281-3. PubMed ID: 18940307
    [No Abstract]   [Full Text] [Related]  

  • 34. ACE2: a new target for cardiovascular disease therapeutics.
    Raizada MK; Ferreira AJ
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):112-9. PubMed ID: 17703127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The antihypertensive effect of peptides: a novel alternative to drugs?
    Hong F; Ming L; Yi S; Zhanxia L; Yongquan W; Chi L
    Peptides; 2008 Jun; 29(6):1062-71. PubMed ID: 18384915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Angiotensin-2 receptor blockade--new therapeutic approach to treatment of hypertension].
    Zimlichman R
    Harefuah; 1996 Jul; 131(1-2):43-5. PubMed ID: 8854479
    [No Abstract]   [Full Text] [Related]  

  • 37. [The clinical use of angiotensin converting enzyme inhibitors].
    Fyhrquist F
    Duodecim; 1986; 102(22):1709-16. PubMed ID: 3026771
    [No Abstract]   [Full Text] [Related]  

  • 38. Captopril avoids hypertension, the increase in plasma angiotensin II but increases angiotensin 1-7 and angiotensin II-induced perfusion pressure in isolated kidney in SHR.
    Castro-Moreno P; Pardo JP; Hernández-Muñoz R; López-Guerrero JJ; Del Valle-Mondragón L; Pastelín-Hernández G; Ibarra-Barajas M; Villalobos-Molina R
    Auton Autacoid Pharmacol; 2012 Oct; 32(3 Pt 4):61-9. PubMed ID: 22994939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution of angiotensin-converting enzyme inhibitors.
    Wyvratt MJ
    Clin Physiol Biochem; 1988; 6(3-4):217-29. PubMed ID: 2849521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Vasoprotective effects of statins and angiotensin II blockers in atherothrombosis].
    Egido J; Ruiz-Ortega M; Muñoz-García B; Martín-Ventura JL; Blanco-Colio LM
    Nefrologia; 2005; 25 Suppl 2():117-28. PubMed ID: 16050414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.